• News

"Dr. Chari On Challenges In Sequencing Agents For Multiple Myeloma" - Ajai Chari, MD

  • Onc Live
  • (December 14, 2017)

Ajai Chari, MD, associate professor of medicine, hematology, medical oncology at the Icahn School of Medicine at Mount Sinai, director of clinical research in the multiple myeloma program and associate director of clinical research at the Mount Sinai Cancer Clinical Trials Office, discusses challenges in sequencing agents for patients with multiple myeloma. According to Dr. Chari, the use of daratumumab (Darzalex) induction therapy and ixazomib (Ninlaro) in the maintenance setting are making patients refractory to a different drug class. Many researchers are investigating how quickly chimeric antigen receptor (CAR) T-cell therapy can be given to patients based on the risk value, explains Dr. Chari.

 - Ajai Chari, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office 

Learn more

Related Articles
Building exterior
Doctor adjusting microscope
Parekh
Doctor adjusting microscope
Doctor adjusting microscope
Myeloma
Researcher using microscope
Treatment resistance
Doctor adjusting microscope
REsearcher using computer
Doctor adjusting microscope